Nisa Investment Advisors
IMDX

Nisa Investment Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Nisa Investment Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,218
Closed -$126K – 2470
2022
Q1 		$126K Sell
4,218
-1,782
-30% -$57K ﹤0.01% 1544
2021
Q4 		$204K Hold
6,000
– – ﹤0.01% 1264
2021
Q3 		$427 Hold
6,000
– – ﹤0.01% 1159
2021
Q2 		$689 Hold
6,000
– – ﹤0.01% 1049
2021
Q1 		$623 Hold
6,000
– – ﹤0.01% 1107
2020
Q4 		$287K Buy
+6,000
New +$220K ﹤0.01% 1341
2020
Q3 		– Sell
-79
Closed -$3K – 2261
2020
Q2 		$3K Buy
79
+33
+72% +$1.7K ﹤0.01% 2040
2020
Q1 		$2K Buy
+46
New +$2.25K ﹤0.01% 2044

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Nisa Investment Advisors's IMDX Position: Q2 2022 in Review

Nisa Investment Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 4,218 shares — an estimated $126K sold.

Nisa Investment Advisors first reported a position in IMDX in Q1 2020 and held it in 8 quarters. The position peaked at $287K in Q4 2020. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Nisa Investment Advisors reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Nisa Investment Advisors sold 4,218 Insight Molecular Diagnostics shares in Q2 2022, an estimated $126K.
  • Nisa Investment Advisors first reported a position in Insight Molecular Diagnostics in Q1 2020 and held it in 8 quarters.
  • Nisa Investment Advisors's Insight Molecular Diagnostics position peaked at $287K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Nisa Investment Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.